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Peripheral arterial disease affects more than 27 million patients in the United 
States [1]. PAD can lead to peripheral limb ischemia and result in non-healing foot 
ulcers. Currently, surgical therapies such a stenting, grafting, and bypass, exist for 
treatment of ischemia, but these treatments are prone to long-term failure. These 
treatments also only successfully yield beneficial results about 25% of the time [2]. 
Alternatively, regenerative therapies that stimulate the growth of new vasculature have 
great potential for treating peripheral and myocardial ischemia. Growth factor based 
therapies that induce neovascularization have shown promising results in animal models, 
but have limited success in clinical trials [3]. This discrepancy is most likely a result of 
growth factor resistance brought on by diseases that lead to peripheral vascular disease 
[4].  Here, we have developed a new method for enhancing the activity of growth factors 
in growth factor resistant disease states such as diabetes and hyperlipidemia. Our novel 
method delivers the growth factor co-receptor glypican-1 embedded in a liposomal 
carrier to create a glypican-1 proteoliposome (a “glypisome”). By co-delivering the co-
receptor glypican-1 along with the growth factor, we hope to overcome growth factor 
resistance associated with long-term disease. Here we optimize glypisome composition to 
 viii 
maximize angiogenic response when co-delivered with growth factors, through the use of 
in vitro endothelial assays and explore what mechanisms bring about this change in 
activity. Then we determine therapeutic potential of co-delivering glypisomes with 
growth factors in vivo by assessing neovascularization in healthy and disease mouse 
models of ischemia. We also explore overcoming disease mediated growth factor 
resistance by delivering glioblastoma-derived exosomes as a naturally occurring 
alternative to the glypisomes that we have developed. We test these exosomes in both in 
vitro endothelial assays and in vivo with a mouse hind limb ischemia model. We 
demonstrate that delivering these co-receptors in conjunction with the growth factor will 
allow us to overcome the disease phenotype and lead to a viable growth factor therapy for 
peripheral arterial disease.  
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Chapter 1: Introduction 
1.1 MOTIVATION 
Peripheral arterial disease (PAD) affects over 200 million people worldwide and 
is estimated to afflict approximately 16% of the general population over 65 years of age. 
Severe PAD has serious consequences for patients including the formation of non-healing 
ulcers, pain from intermittent claudication and, ultimately, increased risk for limb 
amputation. The current clinical treatments for PAD include surgical revascularization 
with bypass grafting or endartectomy, or percutaneous interventions such as angioplasty, 
stenting and atherectomy. However, these procedures cannot be performed in a 
significant portion of patients and many do not respond to these therapies [5]. An 
alternative approach for treating ischemic disease is to stimulate the body to create new 
vasculature to restore blood flow through its own regenerative processes. Several 
approaches have been explored to this end including the delivery of progenitor cells [6], 
viral vectors to express growth factor/angiogenic transcription factor genes [6-15] or 
through the delivery of growth factors [7, 16, 17]. Growth factors as protein therapeutics 
for ischemia have potential advantages from regulatory, production and delivery 
perspectives. However, in practice angiogenic growth factor therapies, both through 
delivered proteins and genes, have led to disappointing results in clinical trials [18]. Thus, 
while the concept of therapeutic angiogenesis has great promise, there are no current 
treatments that are capable of stimulating neovascularization in the context of human 
ischemic disease.  
The presence of diabetes increases the risk of developing PAD by two-fold and 
increases the rate of progression of the disease [5]. Diabetic patients are 5-10 fold more 
likely to need limb amputation due to PAD [19]. The disease processes that drive 
development of ischemia may also induce disruptions in the pathways that are critical to 
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mounting an effective angiogenic response to growth factor therapy. Insulin resistance is 
a hallmark of diabetic disease and, similarly, long-term ischemic vascular disease in aged 
humans may also represent a state in which the body can no longer respond effectively to 
growth factors such as FGF-2 and VEGF in ischemic tissues. We have recently shown 
that many of the heparan sulfate proteoglycans (HSPGs) that serve as co-receptors for the 
FGF-2 and VEGF families of growth factors are expressed at lower levels in ob/ob mice 
than wild type (WT) mice [4]. In addition, heparanase expression is increased in cells 
treated with fatty acids and in animals on a high fat diet [20-23], in atherosclerotic 
plaques [23-25] and following stenting or vascular injury [26, 27]. Heparanase is an 
enzyme that can degrade the heparan sulfate chains on cell surface proteoglycans [28, 
29], ultimately leading to enhanced surface shedding of these molecules and loss of their 
activity as co-receptors for growth factor signaling [30, 31]. Thus, many disease states 
and pathophysiological processes lead to the loss of HSPGs from the cell surface.  
In this study, we have examined the expression of the cell surface proteoglycan 
glypican-1 in disease and explored its use as a therapeutic enhancer for angiogenic 
growth factor delivery. The glypicans are distinguished from other cell surface HSPGs by 
their linkage to the membrane through a glycosylphosphatidylinositol (GPI) anchor. This 
GPI linker enables the phospholipase mediated-shedding of glypicans and drives 
preferential localization of the protein in cholesterol-rich lipid rafts [32]. These properties 
allow glypicans to associate with calveolae [33], control endocytosis/recycling and 
transcellular transport [34-37], regulate the formation of morphogen gradients [38, 39] 
and facilitate growth factor cell signaling [40-43]. Glypican-1, in particular, is highly 
expressed in gliomas and their associated vasculature [44, 45]. A hallmark of gliomas is 
vigorous angiogenic response to the tumor that drives neovascularization through 
multiple mechanisms [34-37]. Glypican-1 has a key role in the growth, metastasis and 
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angiogenic properties of gliomas [44-47]. In addition, glypican-1 is the most prevalent 
member of the glypican family expressed in endothelial cells and the vascular system 
[48]. It can act as a co-receptor/modulator for many angiogenic factors including 
members of the FGF and VEGF growth factor families [44, 48-51]. Several studies also 
have shown that glypican-1 can stimulate cell cycle progression in endothelial cells [47, 
52]. In this work, we show that glypican-1 is lost in the blood vessels of skin samples 
from human patients with type 2 diabetes. We developed a novel therapeutic that consists 
of glypican-1 embedded in a nanoliposomal carrier (a “glypisome”) that can be locally 
delivered to ischemic tissues from an alginate gel to potentiate the angiogenic response to 
localized growth factor therapies in diseased tissues. We demonstrate that this therapeutic 
enhancer improves the in vitro activity of FGF-2 and VEGF in endothelial cells through 
multiple mechanisms. When locally delivered from an alginate gel, glypisomes also 
enhance the therapeutic potential of FGF-2 therapy leading to increased revascularization 
of ischemic limbs in wild type and diabetic mice.  
Exosomes are nanoparticles that are secreted by cells into their environment and 
range from approximately 30 to 100 nm in diameter [53]. These secreted extracellular 
vesicles are formed initially by formation of invaginations in the endosomal membrane to 
create a multivesicular body (MVB )[54]. This process is in contrast to the that for 
microvesicles (200-1000 nm in diameter) that are formed by membrane shedding[55]. If 
true/exclusive exosomes are released through multivesicular endosomal fusion with the 
plasma membrane and are found in many biofluids. Extracellular vesicles were initially 
discovered in several research fields with varying nomenclature. These secreted vesicles 
have now been recognized as mediators of cell-cell communication, capable of delivering 
molecules between distant cells [56]. Exosomes, in particular are known to have high 
levels of tetraspanins, trafficking/export-related molecules and heat shock proteins[57-
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60]. In addition, exosomes contain proteins, microRNA (miRNA) and, in some cases, 
double stranded DNA [61, 62]. Exosomes also carry bioactive lipids including 
sphingomyelin, eicosanoids, cholesterol and ganglioside GM3 [63]. Extracellular vesicles 
including exosomes are efficiently taken up by cells in culture where they modify the 
target cells transcriptional and protein expression profiles.  
In particular, exosomes from many cell types have been known to mediate 
angiogenesis [64-69]. Exosomes derived from mesenchymal stem cells have also been 
shown to induce angiogenesis and modulate revascularization in ischemia and wound 
healing [68, 69]. Glioblastoma is one of the most angiogenic tumors, induce an intense 
growth of surrounding blood vessels [70]. The exosomes secreted by glioblastoma cells 
prime endothelial cells to respond to hypoxic conditions with an angiogenic response 
[71]. Moreover, primary glioblastoma cells carry angiogenic miRNAs and proteins that 
facilitate angiogenic differentiation of endothelial cells [72]. Extracellular vesicles from 
glioblastoma cells have been shown to carry proteins that have both oncogenic and tumor 
suppressive activities including EGF receptors, PDGFR-A and PTEN [72-75]. Thus, 
while it is well supported that glioblastoma exosomes enhance angiogenesis it is less 
clear what role they play in tumor progression and metastasis. In addition, glioma-derived 
exosomes have immunomodulatory effects and drive macrophages towards the M2-
phenotype [76]. Macrophages polarized towards the M2-phenotype secrete VEGF and 
promote angiogenesis [77, 78]. 
 Exosomes are an emerging therapeutic strategy and have been explored as 
direct treatments for disease and drug carriers [79-82]. Exosomes from mesenchymal 
stem cells have generated significant interest and have been used to induce angiogenesis 
in wound healing and in ischemia [69, 83]. In addition, mesenchymal stem cell exosomes 
have improved the recovery following myocardial infarction and enhance cardiac 
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regeneration [84, 85]. In this study, we aimed to examine using glioblastoma exosomes as 
therapeutics for enhancing revascularization in peripheral limb ischemia. Glioblastoma is 
one the most highly vascularized solid tumors and produces an intense angiogenic 
response. Moreover, the exosomes produced by these cells have been linked to growth 
promoting signals in endothelial cells.[86] Here, we explored whether this powerful 
aspect of tumor biology could be harnessed to enhance angiogenic therapies for patients 
with peripheral vascular disease.  
 
1.2 DISSERTATION ROADMAP 
This dissertation is laid out such that chapter one is an introduction to the 
motivation for the work. Chapter two contains the relevant background for the projects 
described in the subsequent chapters. Chapter three describes the fabrication, 
characterization and optimization of the glypisomes using in vitro assays of angiogenesis. 
Chapter four describes in vivo analysis of the angiogenic potential of the glypisomes as a 
treatment for peripheral vascular disease using a murine hind limb ischemia model. 
Chapter five details the therapeutic potential of a naturally occurring glypisome-like-
particle, glioblastoma exosomes, for therapeutic angiogenesis in peripheral limb 
ischemia. This chapter describes the isolation and characterization as well as in vitro and 
in vivo validation of these exosomes as a potential therapeutic. Finally, chapter six 
contains the conclusions from this work and future directions to further explore these 
therapies. 
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Chapter 2: Background 
2.1 PERIPHERAL VASCULAR DISEASE 
Peripheral arterial disease (PAD) affects more than 27 million patients in the 
United States [1].  It is characterized by arterial narrowing due to plaque buildup, 
reducing blood flow in the affected tissues. This leads to poor oxygenation and a buildup 
of metabolic by products. PAD can lead to peripheral limb ischemia and result in non-
healing foot ulcers, and is associated with increased risk of myocardial infarction, critical 
limb ischemia, stroke, and death due to a cardiovascular related event.  Patients with 
critical limb ischemia, which is characterized by resting pain in the lower extremities, 
have a 25% chance of amputation and/or cardiovascular related mortality within the year 
of diagnosis. Five years after developing critical limb ischemia the likelihood of 
cardiovascular mortality leaps to 60% [87]. Increased risk for developing PAD is 
associated with smoking, hypertension, diabetes, high cholesterol, sedentary behavior and 
obesity [88, 89]. There are several methods for diagnosing PAD; ankle-brachial index, 
doppler ultrasound, magnetic resonance angiogram, and arteriogram may be employed to 
detect the disease. Skin perfusion measurements are also an indicator of critical limb 
ischemia [90]. 
Currently, surgical therapies such a stenting, grafting, and bypass, exist for 
treatment of ischemia, but these treatments are prone to long-term failure and are not 
always an option for patients due to other comorbidities [2]. These treatments are also 
only successfully yield beneficial results about 25% of the time [2]. Alternatively, 
regenerative therapies that stimulate the growth of new vasculature have great potential 
for treating peripheral and myocardial ischemia. Growth factor based therapies that 
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induce neovascularization have shown promising results in animal models, but have 
limited success in clinical trials [3]. This discrepancy is most likely a result of growth 
factor resistance associated brought on by diseases that lead to peripheral vascular disease 
[4].    
2.2 ANGIOGENESIS 
Angiogenesis is the formation of new vasculature from by branching off of the 
existing vascular network. Therapeutic angiogenesis can be achieved by introducing stem 
cells or growth factors to stimulate new vascular formation. This leads to an increase in 
blood flow in the area. There are several ways in which this can occur; growth factors can 
be upregulated by gene therapy or by local delivery of the growth factors. Growth factors 
that are targeted to induce angiogenesis are, vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and hepatocyte 
growth factor (HGF) [91-95].  There are several concerns associated with a gene therapy 
approach, such as controlling gene integration in to the target cells. Also due to the 
complexity of angiogenesis it is possible that a single gene target may not be effective to 
overcome challenges posed by the disease. 
Stem cell therapies have also been explored. There is evidence that injecting 
mesenchymal stem cells into ischemic tissue leads to angiogenesis in this tissue [96-99]. 
It is thought that this result is due to both direct incorporation of these cells into the 
vascular network, and by the proangiogenic signals that these cells produce. Stem cell 
therapies are particularly attractive as they could use an autologous source for these cells. 
While attractive, stem cell therapies still are not quite well developed enough for 
effective and controlled treatments. 
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2.3 GLYPICAN-1 
Glypican-1 is a cell surface heparan sulfate proteoglycan (HSPG). HSPGs are cell 
surface proteins that consist of a core protein with covalently attached heparan sulfate 
chains or glycosaminoglycans. The glypicans are distinguished from other cell surface 
HSPGs by their linkage to the membrane through a glycosylphosphatidylinositol (GPI) 
anchor. This GPI linker enables the phospholipase mediated-shedding of glypicans and 
drives preferential localization of the protein in cholesterol-rich lipid rafts [32]. These 
properties allow glypicans to associate with calveolae [100], control 
endocytosis/recycling and transcellular transport [101-104], regulate the formation of 
morphogen gradients [105, 106] and facilitate growth factor cell signaling [107-110]. 
Glypican-1, in particular, is highly expressed in gliomas and their associated vasculature 
[111, 112]. A hallmark of gliomas is vigorous angiogenic response to the tumor that 
drives neovascularization through multiple mechanisms [101-104]. Glypican-1 has a key 
role in the growth, metastasis and angiogenic properties of gliomas [111, 113, 114]. 
Glypican-1 has also been used to identify cancer cell derived exosomes[115]. It can act as 
a co-receptor/modulator for many angiogenic factors including members of the FGF and 
VEGF growth factor families [111, 116-118]. 
2.4 EXOSOMES 
Exosomes are extracellular vesicles released by cells into their environment that 
range from 30-100 nm in diameter. They are released via multivesicular endosomal 
fusion with the plasma membrane [119, 120] and are found in many different types of 
biofluids. They contain proteins, microRNA, and DNA. Exosomes have been shown to 
facilitate intracellular signaling by delivering the protein and RNA [119, 121, 122]. We 
have decided to focus on glioblastoma exosomes because glioblastoma is one of the most 
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vascular solid tumors [123]. Exosomes from glioblastoma have also been shown to 
release the pro-angiogenic signal miR-124 [124]. 
2.5 MOUSE MODELS 
In these studies, C57Bl/6 mice were used as a healthy model or wild type (WT). 
C57Bl/6 mice are the most widely used strain of mice and is one of the earliest species to 
have its genome sequenced. To model the disease state we will use B6.Cg-Lepob/J (ob/ob) 
or leptin deficient mice, and originate from the C57Bl/6 strain. These mice are leptin 
deficient and characterized by obesity, hyperglycemia and hyperlipidemia. The obesity in 
these mice is characterized by both an increase in size and number of adipocytes. While 
hyperphagia leads to obesity in these mice, they will gain excess fat deposits even on a 
restricted diet. The ob/ob mice have been shown to have glucose intolerance, elevated 
plasma insulin and impaired wound healing and are a good model for diabetes. Our lab 
has also shown that these mice exhibit disease induced growth-factor resistance to FGF-2 
and VEGF [4]. For these reasons we have chosen them as our disease model. 
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Chapter 3: Development of Glypican-1 Proteoliposomes 
3.1 INTRODUCTION 
Peripheral arterial disease (PAD) affects over 200 million people worldwide and 
is estimated to afflict approximately 16% of the general population over 65 years of age. 
Severe PAD has serious consequences for patients including the formation of non-healing 
ulcers, pain from intermittent claudication and, ultimately, increased risk for limb 
amputation. The current clinical treatments for PAD include surgical revascularization 
with bypass grafting or endartectomy, or percutaneous interventions such as angioplasty, 
stenting and atherectomy. However, these procedures cannot be performed in a 
significant portion of patients and many do not respond to these therapies [5]. An 
alternative approach for treating ischemic disease is to stimulate the body to create new 
vasculature to restore blood flow through its own regenerative processes. Several 
approaches have been explored to this end including the delivery of progenitor cells [6], 
viral vectors to express growth factor/angiogenic transcription factor genes [6-15] or 
through the delivery of growth factors [7, 16, 17]. Growth factors as protein therapeutics 
for ischemia have potential advantages from regulatory, production and delivery 
perspectives. However, in practice angiogenic growth factor therapies, both through 
delivered proteins and genes, have led to disappointing results in clinical trials [18]. Thus, 
while the concept of therapeutic angiogenesis has great promise, there are no current 
treatments that are capable of stimulating neovascularization in the context of human 
ischemic disease.  
The presence of diabetes increases the risk of developing PAD by two-fold and 
increases the rate of progression of the disease [5]. Diabetic patients are 5-10 fold more 
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likely to need limb amputation due to PAD [19]. The disease processes that drive 
development of ischemia may also induce disruptions in the pathways that are critical to 
mounting an effective angiogenic response to growth factor therapy. Insulin resistance is 
a hallmark of diabetic disease and, similarly, long-term ischemic vascular disease in aged 
humans may also represent a state in which the body can no longer respond effectively to 
growth factors such as FGF-2 and VEGF in ischemic tissues. We have recently shown 
that many of the heparan sulfate proteoglycans (HSPGs) that serve as co-receptors for the 
FGF-2 and VEGF families of growth factors are expressed at lower levels in ob/ob mice 
than wild type (WT) mice [4]. In addition, heparanase expression is increased in cells 
treated with fatty acids and in animals on a high fat diet [20-23], in atherosclerotic 
plaques [23-25] and following stenting or vascular injury [26, 27]. Heparanase is an 
enzyme that can degrade the heparan sulfate chains on cell surface proteoglycans [28, 
29], ultimately leading to enhanced surface shedding of these molecules and loss of their 
activity as co-receptors for growth factor signaling [30, 31]. Thus, many disease states 
and pathophysiological processes lead to the loss of HSPGs from the cell surface.  
In this study, we have examined the expression of the cell surface proteoglycan 
glypican-1 in disease and explored its use as a therapeutic enhancer for angiogenic 
growth factor delivery. The glypicans are distinguished from other cell surface HSPGs by 
their linkage to the membrane through a glycosylphosphatidylinositol (GPI) anchor. This 
GPI linker enables the phospholipase mediated-shedding of glypicans and drives 
preferential localization of the protein in cholesterol-rich lipid rafts [32]. These properties 
allow glypicans to associate with calveolae [33], control endocytosis/recycling and 
transcellular transport [34-37], regulate the formation of morphogen gradients [38, 39] 
and facilitate growth factor cell signaling [40-43]. Glypican-1, in particular, is highly 
expressed in gliomas and their associated vasculature [44, 45]. A hallmark of gliomas is 
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vigorous angiogenic response to the tumor that drives neovascularization through 
multiple mechanisms [34-37]. Glypican-1 has a key role in the growth, metastasis and 
angiogenic properties of gliomas [44-47]. In addition, glypican-1 is the most prevalent 
member of the glypican family expressed in endothelial cells and the vascular system 
[48]. It can act as a co-receptor/modulator for many angiogenic factors including 
members of the FGF and VEGF growth factor families [44, 48-51]. Several studies also 
have shown that glypican-1 can stimulate cell cycle progression in endothelial cells [47, 
52]. In this work, we show that glypican-1 is lost in the blood vessels of skin samples 
from human patients with type 2 diabetes. We developed a novel therapeutic that consists 
of glypican-1 embedded in a nanoliposomal carrier (a “glypisome”) that can be locally 
delivered to ischemic tissues from an alginate gel to potentiate the angiogenic response to 
localized growth factor therapies in diseased tissues. We demonstrate that this therapeutic 
enhancer improves the in vitro activity of FGF-2 and VEGF in endothelial cells through 
multiple mechanisms. When locally delivered from an alginate gel, glypisomes also 
enhance the therapeutic potential of FGF-2 therapy leading to increased revascularization 
of ischemic limbs in wild type and diabetic mice.  
3.2 MATERIALS AND METHODS 
3.2.1 Human Tissue, Immunostaining 
Human skin samples were obtained from the Glasgow Caledonian University 
Skin Research Tissue Bank, Glasgow UK. The tissue bank has NHS research ethics to 
supply human skin for research (REC REF: 11/S1402/2). Samples were formalin fixed 
and embedded in paraffin following standard procedures prior to sectioning.  Six skin 
samples were collected from non-diabetic patients and seven skin samples from those 
with type 2 diabetes. Human skin tissue samples were cut with a microtome to obtain 6 
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µm thick sections were then stained using hematoxylin and eosin for overall morphology. 
The sections were deparaffinized and treated for 3 hours with antigen retrieval solution 
(Dako) at 80°C. The sections were cooled to room temperature and blocked with 20% 
fetal bovine serum for 45 minutes and then immunostained with the Envision+ Dual Link 
Kit (Dako) using a 1:100 dilution of primary antibody to PECAM-1 (Millipore) or a 
1:500 dilution of primary antibody to glypican-1 (Thermo Scientific). Following staining, 
the samples were imaged using a bright field microscope (Meiji). For human skin 
samples, we defined DAB intensity for positive staining and counted the number of cells 
positive for glypican-1 staining in the arterioles in the skin. 
3.2.2 Cell Culture 
Human umbilical vein endothelial cells (HUVECs) were cultured in MCDB-131 
media with 7.5% FBS, EGM-2 supplements (Lonza), L-glutamine and antibiotics. 
Endothelial cells that were used for the experiments did not exceed passage six. HeLa 
cells (ATCC) were cultured in high glucose DMEM with 10% FBS, L-glutamine and 
antibiotics. For lentiviral production, HEK293T cells were cultured in DMEM with 
sodium pyruvate, 10% FBS, L-glutamine and antibiotics. 
3.2.3 Preparation of Glypisomes 
For the production of recombinant glypican-1, HeLa cells were transduced with a 
lentiviral vector with constitutive expression of 6x-His tagged glypican-1. Viruses were 
produced in HEK 293T cells using a human lentiviral packaging system according to the 
manufacturer’s instructions (Genecopoeia). The cells were then selected with puromycin 
to create a stable cell line. The cells were lysed in a buffer containing 20 mM Tris (pH 
8.0), 150 mM NaCl, 1% Triton X-100, 2 mM sodium orthovanadate, 2 mM PMSF, 50 
mM NaF, and protease inhibitors (Roche) at room temperature. Glypican-1 was then 
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isolated using a Ni Sepharose column (His SpinTrap Kit; GE Healthcare). The buffer was 
exchanged and protein concentrated using Centriprep concentrators (Millipore). The final 
working concentration of protein was found to be 61 µg/ml using a micro BCA Protein 
Assay kit (Thermo Scientific). Purity of the protein was confirmed by SDS-PAGE 
followed silver staining of the gel (Figure 3.1). We then mixed lipid stock solutions (10 
mg/ml in chloroform) of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), cholesterol and sphingomyelin in a 
volumetric ratio of 2:1:1:1, respectively, in a round bottom flask. The solvent was 
removed using rotary evaporation and the lipid film further dried under argon gas. The 
film was resuspended in HEPES buffer by vortexing, sonication and three cycles of 
freeze thawing (total lipid concentration of 12.3 mM).  The lipid solution was then 
extruded through a 400 nm polycarbonate filter membrane to create liposomes. The 
liposome solution was mixed to varying volumes of glypican-1 (61 µg/ml) and 1% n-
octyl-β-D-glucopyranoside. The detergent was extracted to allow glypican-1 
incorporation into the liposome membrane through progressive dilution, dialysis and 
zeolite treatment. Every 30 minutes the concentration of the solution was reduced 10% by 
adding PBS to a final concentration of 40% of the original solution. The excess protein 
and detergent were then removed extensive dialysis and the final solution treated with 
Biobeads (SM-2; Bio-Rad) to remove any residual detergent. The final concentration of 
the glypisomes contained 664 µg/ml of the lipid solution and 19.5 µg/ml of the glypican-
1 at the end of this process.   
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Figure 3.1  Isolation of recombinant glypican-1. (A) Silver stained gel of isolated  
glypican-1. L: molecular weight (MW) ladder labeled in kDa. Lane 1: whole 
lysate from HeLa cells. Lane 2: Whole lysates from glypican-1 over-
expressing HeLa cells. Lane 3: isolated glypican-1. (B) Western blot for 
glypican-1 for the total sample (Lane 1) and the isolated glypican-1 (Lane 
2).  
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3.2.3 Immunoblotting and Silver Staining 
Following the various treatments, cells were lysed in a solution containing the 
following: 20 mM Tris at pH 8, 150 mM NaCl, 1% triton, 0.1% SDS, 2 mM sodium 
orthovanadate, 2 mM PMSF, 50 mM NaF, and protease inhibitors (Roche). For tissue 
samples, cryosections were collected, and the sections placed into the above lysis buffer 
and homogenized using a Tissuelyzer device (Qiagen). Lysates from cells or tissues were 
clarified with centrifugation, normalized for protein concentration and separated on 
Nupage Novex 10% Bis-Tris gels (Lifetech). Samples were then transferred using the 
iBlot System to a nitrocellulose membrane using the iBlot Gel Transfer Stacks (Life 
Technologies). The membrane was washed twice in phosphate buffered saline with 0.1% 
tween (PBST). The membranes were then incubated at 4°C overnight in a 1:500 dilution 
of glypican-1 antibody (Abcam), phospho-ERK, ERK, phosphor-AKT or AKT 
antibodies (Cell Signaling). Membranes were washed twice in PBST and incubated with 
an appropriate HRP-linked secondary antibody at 1:5000 dilution for two hours at room 
temperature. The membranes were washed extensively in PBST and imaged using the 
Femto Maximum Sensitivity Substrate (Thermo Scientific) with a FluorChem HD2 
System (Cell Biosciences). Silver staining was performed on gels using a silver staining 
kit according to the manufacturer’s instructions (Thermo Scientific). 
3.2.4 Liposomal Characterization 
The size and dispersion of the isolated glypican-1 and liposomes was 
characterized by dynamic light scattering (Malvern Zetasizer Nano ZS). Calibration was 
performed using 54 nm polystyrene particles. Results shown are the average of 50 
measurements. To visualize the glypisomes, carbon support grids (300 mesh Cu; EM 
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Sciences) were treated with glow discharge at 50 mA for two minutes (Emitech K100x; 
Quorum Technologies). The samples were then applied to the grids and the excess liquid 
removed with a filter paper. The grids were then stained with a 2% uranyl acetate 
solution and imaged using an FEI Tecnai Transmission Electron Microscope (TEM).  
3.2.5 FGF-2 Trafficking and Rab Co-localization Assays 
Constructs for expressing GFP-Rab5, GFP-Rab7 and GFP-Rab11 were as 
described previously [125, 126]. A construct to express GFP-Rab11 was created using 
similar methods. For studying the effect of glypisomes on endosomal trafficking, HEK 
293 cells were plated on glass bottom dishes and transfected with the constructs using 
lipofectamine 2000 (Life Technologies, inc.). We conjugated Alexa Fluor 594 to FGF-2 
while it was bound to heparin column to prevent loss of activity as described previously 
[127]. Twenty-four hours after transfection, 27 ng/ml of labeled FGF-2 was added. The 
cells were fixed at various time points after the addition of FGF-2 and then imaged using 
a laser scanning confocal microscope (LSM 710; Zeiss). The percentage Rab-positive 
endosomes that also contained FGF-2 was quantified using 10 cells at each time point (all 
Rab-positive endosomes were counted for each cell). The total fluorescence intensity and 
nuclear intensity of FGF-2 was calculated by selecting the whole cell or DAPI-stained 
nucleus and measuring intensity in exposure normalized images using Photoshop 
software (Adobe).  
3.2.6 Cell Proliferation Assay 
Endothelial cells were passaged into a 96-well plate and cultured in low serum 
media with 2% FBS for 24 hours. Glypisomes and/or growth factors were then added to 
cells. After 24 hours, BrdU was added to the cells and proliferation was assessed 12 
hours later using a colorimetric BrdU assay (Cell Signaling, Inc.). For the temporal bead 
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release study 27,000 endothelial cells/well were plated in a 12 well plate and an alginate 
bead containing either FGF-2 or glypisomes was added to the well, at each time point the 
number of cells were counted using a hemocytometer and normalized to the initial cell 
count. 
3.2.7 Wound Healing Cell Migration Assay 
Endothelial cells were grown to confluence and then cultured in low serum media 
(2% FBS) for 24 hours. A cell scraper was used to create a wound in each well. The 
glypisomes were added with FGF-2 (10 ng/ml) or VEGF-A (10 ng/ml) immediately after 
wounding of the monolayer. The wounds were imaged along their entire length using an 
inverted, phase-contrast microscope with digital camera immediately after wounding and 
six hours later. The average gap was calculated using Metamorph software (Molecular 
Devices) the rate of wound closure was calculated by taking the difference between the 
two measurements. 
3.2.8 In Vitro Angiogenic Differentiation Assay 
Multi-well culture plates were coated with growth factor depleted Matrigel (BD 
Biosciences) and allowed to gel for one hour at 37°C. In each well, endothelial cells were 
plated at a concentration of 2x104 cells per well in 24-well plates. The cells were treated 
with the various combinations of glypisomes and growth factors. The cells were imaged 
after 16 hours and then quantified for average tubule length, number of tubules, and 
number of tubule branching points were then quantified using Metamorph software 
(Molecular Devices). 
3.2.9 Preparation of Alginate Beads, Measurement of Release Kinetics  
Equal volumes of a 4% sodium alginate solution and a 0.85% NaCl solution were 
mixed together. The glypisomes (1:100 dilution) and FGF (1.5 µg/100 µl) were added to 
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this solution. Beads were created by controlled extrusion into a 1.1% CaCl2 solution 
through a 30G needle using a syringe pump. The beads were allowed to crosslink for 1 
hour at 4°C. For measuring the release kinetics, alginate beads were put into plastic 
scintillation vials containing PBS with calcium and magnesium chloride. At various time 
points the liquid was completely removed, replaced and the harvested liquid frozen at -
80C. The FGF-2 released was quantified using ELISA (R&D Systems). Glypican-1 
release was quantified using an ELISA (Ray Biotech).  
3.2.10 Scanning Electron Microscopy 
To examine the morphology of the alginate gels, the samples were flash frozen in 
liquid nitrogen (-195°C) and lyophilized overnight (-110°C; 0.0005 mbar) in scintillation 
vials. The freeze-dried gels were sputter coated with gold discharge for 30 seconds and 
then loaded on the stage to image them under the scanning electron microscope (FEI 
Quanta 650 ESEM) with an acceleration voltage of 10 kV. 
3.2.11 Statistical Analysis 
All results are shown as mean ± standard error of the mean. Comparisons between 
only two groups were performed using a two-tailed Student’s t-test.  Multiple 
comparisons between groups were analyzed using a two-way ANOVA followed by 
Dunnett post-hoc testing. A two-tailed probability value of p < 0.05 was considered 
statistically significant. 
3.3 RESULTS 
3.3.1 Glypican-1 is Reduced in the Blood Vessels of Skin Tissues from Diabetic 
Patients 
Our recent studies have shown that there are reduced protein levels of the 
syndecan family of cell surface heparan sulfate proteoglycans in diabetic mice on a high 
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fat diet [4]. This finding led us to hypothesize that loss of growth factor co-receptors, 
including glypican-1, is a key mechanism in diabetes-mediated growth factor resistance. 
To test if a similar phenomenon was happening in humans with diabetes, we collected 
skin samples from human patients and immunostained sections from these samples for 
glypican-1 (Figure 3.2A; Table 3.1). This analysis revealed a significant reduction in the 
number of glypican-1 positive cells in the arterioles from the skin of patients with type 2 
diabetes (Figure 3.2B). Consistent with these findings, we performed western blotting on 
tissues from ob/ob and wild type mice that had been exposed to a high fat diet to 10 
weeks and found a reduced amount of glypican-1 in ob/ob mice versus wild type mice 
with a high fat diet (Figure 3.3). Glypican-1 serves as a co-receptor for angiogenic 
growth factors and, consequently, its loss may lead to reduced growth factor 
responsiveness. To overcome this mechanism of therapeutic resistance, we created a 
protein therapeutic formulation of glypican-1 by embedding it in the lipid membrane of a 
liposome that allows it to be co-delivered with growth factors (“glypisomes”; Figure 3.4). 
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Figure 3.2  Glypican-1 is reduced in mice and human with diabetes. (A) 
Immunostaining for glypican-1 in skin samples from diabetic and non-
diabetic patients. (B) Analysis of the number of DAB positive nuclei within 
arterioles within the skin.  *Statistically significant different from the no 
growth factor and growth factor alone groups (p < 0.05). Bar = 50 mm. 
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Table 3.1 Table of human skin sample patient data. 
 
!
! ! ! !
Table 1. Patient Sample Data 
Diabetes Status Age Sex 
Normal 59 M 
Normal 49 F 
Normal 69 M 
Normal 62 M 
Normal 80 F 
Normal 39 F 
Diabetic, type II 73 M 
Diabetic, type II 47 F 
Diabetic, type II 80 M 
Diabetic, type II 81 M 
Diabetic, type II 53 M 
Diabetic, type II 61 M 
Diabetic, type II 67 M 
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Figure 3.3  Glypican-1 is reduced in mice and human with diabetes. Wild type (WT) or 
ob/ob mice were given a normal or high fat diet for 10 weeks and then the 
tissue isolated. The tissues were sectioned and then lysed for western blot 
analysis. (A) Glypican-1 expression in the skeletal muscle of WT and ob/ob 
mice on a normal chow diet (NCD) or high fat diet (HFD). (B) Expression 
of glypican-1 in the cardiac muscle of WT and ob/ob mice. 
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Figure 3.4  Overall diagram of glypisome-based therapeutics for the treatment of 
ischemia. Recombinant glypican-1 is embedded in a liposome membrane 
using detergent extraction. This construct is then combined with growth 
factors and polymerized into an alginate gel for delivery. 
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3.3.2 Synthesis of Glypisomes and Characterization of Release Kinetics from 
Alginate Carrier 
To create glypisomes, we produced and isolated recombinant glypican-1 and then 
embedded the proteins in the membranes of 400-nm liposomes using the progressive 
detergent extraction method (Figure 3.5A; Figure 3.1). For delivery, the glypisomes were 
encapsulated in an alginate gel (Figure 3.5B). We created a set of glypisomes with 
varying lipid:protein ratio, ranging from 100% liposomes with no glypican-1 (L100:G0) 
to the isolated glypican-1 protein alone (L0:G100). We examined the size distribution of 
the glypisomes using transmission electron microscopy (TEM) and dynamic light 
scattering (DLS; Figure 3.6). As anticipated, the liposomes and glypisomes had a size 
distribution near to the 400-nm diameter of the liposomes following the initial extrusion 
step. Surprisingly, the isolated glypican-1 alone had a size of around 190 nm in diameter. 
This result suggests that self-association occurs for isolated glypican-1 and/or the co-
isolation of lipids that creates an aggregate that has a diameter similar to that of the 
liposomal embedding particles. We analyzed the isolated glypican-1 for cholesterol to see 
if there was association of lipid rafts with the glypican-1 and this analysis revealed 
undetectable levels of cholesterol (data not shown). We encapsulated the mid-range 
composition glypisomes (L20:G80) in an alginate gel combined with FGF-2 and 
measured the release of FGF-2 over time using ELISA. The incorporation of glypisomes 
led to a similar response compared to FGF-2 alone, with a slight increase in the release of 
FGF-2 for the later time points out to 14 days (Figure 3.7A). The release profile for 
glypican-1 from these beads was slower than that of FGF-2, likely reflecting the larger 
size of the proteoliposome (Figure 3.7B).  
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Figure 3.5  Characterization of glypisomes and alginate delivery gel. (A) Visualization 
of glypisomes and isolated glypican-1 (GPC1) by transmission electron 
microscopy. Bar = 200 nm. (B) Scanning electron microscopy visualization 
of the alginate gel after polymerization. Left bar = 100 µm and right bar = 
30 µm. 
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Figure 3.6  Dynamic light scattering of isolated glypican-1 (GPC1), liposomes and 
glypisomes. Glypisomes are listed as composition ratio between lipid (L%) 
and protein (P%).  
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Figure 3.7 (A) Release kinetics of FGF-2 from alginate gel with and without 
glypisomes added. (B) Release kinetics of glypican-1 from alginate gels 
containing FGF-2 and glypisomes.   
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3.3.3 Glypisomes Enhance Proliferation and Migration of Endothelial Cells 
Stimulated with FGF-2 or VEGF 
To optimize the effects of glypisome composition on activity, we measured the 
ability of glypisomes to enhance FGF-2 or VEGF activity in a proliferation assay. For 
FGF-2, glypisomes with higher levels of glypican-1 enhanced FGF-2 induced 
proliferation of endothelial cells by nearly three-fold (Figure 3.8). Notably, the liposome 
alone had an enhancing effect on proliferation in comparison to FGF-2, an effect we had 
observed in previous studies using a similar liposome formulation [127]. Interestingly, 
isolated glypican-1 also increased proliferation but not to the full extent as the mid-range 
composition glypisomes. In contrast, VEGF-induced proliferation was not significantly 
altered by the addition of liposome or glypisomes (Figure 3.8). The isolated glypican-1 
reduced the proliferation in response to VEGF to baseline levels. Glypisomes and 
isolated glypican-1 had only small effects on endothelial proliferation in the absence of 
growth factors (Figure 3.9). Human endothelial cells treated with glypisomes or FGF-2 
with glypisomes encapsulated within an alginate bead show a significant increase in 
proliferation after one day and FGF-2 and glypisomes show a significant increase in 
proliferation over alginate alone and glypisomes after the second day (Figure 3.10). In 
addition, we examined the effect of the glypisomes on the migration of endothelial cells 
in an in vitro scratch wound assay. We found that for the L20:G80 composition of 
glypisomes there was no enhancement of FGF-2 induced migration but VEGF induced 
migration was increased (Figure 3.11). We found that glypisomes in the absence of 
growth factors have no significant effect on endothelial migration (Figure 3.12).  
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Figure 3.8  Proliferation of human endothelial cells after stimulation with growth 
factors and glypisomes with varying ratios between lipid and recombinant 
glypcian-1 (GPC-1). Endothelial cells were treated with 10 ng/ml FGF-2 or 
10 ng/ml VEGF165 and glypisomes, and then proliferation was measured 
from BrdU incorporation assay. *Statistically significant difference between 
group and the no growth factor group (p < 0.05). †Statistically significant 
different from the no growth factor and growth factor alone groups (p < 
0.05).  
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Figure 3.9 Effect of glypican-1 and glypisomes on endothelial cell proliferation in the 
absence of growth factors. Proliferation of human endothelial cells after 
stimulation with varying ratios between lipid and recombinant glypican-1 
(GPC-1). Cells were treated with the glypisomes, FGF-2 (10 ng/ml) 
treatment was used as a positive control. *Statistically significant difference 
from FGF-2 treated cells and cells treated with liposomes without glypican-
1 (p < 0.05). 
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Figure 3.10  Human endothelial cells were treated with an alginate bead containing FGF-
2 and/or glypisomes. The number of cells/well was counted at each time 
point. *Statistically significant difference between group and alginate alone 
(p <0.05). †Statistically significant difference between group and FGF-2 (p < 
0.05). ‡Statistically significant difference between group and glypisomes (p 
< 0.05). 
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Figure 3.11 Wound closure after scratch wounding of an endothelial monolayer. Cells 
were treated with 10 ng/ml FGF-2 or 10 ng/ml VEGF at the time of injury. 
The glypisomes (G1PL) with a lipid to glypican-1 protein ratio of 20:80 
were used. *Statistically significant different from the no growth factor and 
growth factor alone groups (p < 0.05). Bar = 200 µm. 
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Figure 3.12 Effect of glypisomes on endothelial cell migration in the absence of growth 
factor. Wound closure after scratch wounding a human endothelial 
monolayer. Cells were treated with either glypisomes or FGF-2 (10 ng/ml) 
at the time of injury. Glypisomes with a lipid to glypican-1 protein ratio of 
20:80 were used in the studies. 
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3.3.4 Glypisomes Enhance FGF-2 Induced In-Vitro Tube Formation 
We next examined the effect of glypisome treatment on growth factor activity in 
an in vitro tube formation assay of angiogenic differentiation. Endothelial cells were 
grown on growth factor depleted matrigel, serum starved and then treated with growth 
factors or growth factors in combination with the glypisomes of varying composition. For 
glypisomes in combination with FGF-2 there was a marked increase in branch points, 
tube length and number of tubes formed in cells treated with the glypisomes with higher 
levels of glypican-1 (Figure 3.13). When glypisomes were delivered with VEGF we 
found they enhanced tube length with midrange concentrations of glypican-1 (60:40 and 
40:60 lipid to protein ratio; Figure 3.14). Isolated glypican-1 also increased VEGF-
induced differentiation but to a lesser extent than the midrange composition glypisomes. 
There were no significant alterations in the number of branch points and number of tubes 
with glypisome treatment in combination with VEGF.  
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Figure 3.13 Glypisomes enhance FGF-2 induced endothelial tube formation. Endothelial 
cells grown on growth factor reduced matrigel and the cells were treated 
with glypisomes with varying composition and 10 ng/ml FGF-2. After 16 
hours the formation of tubes was assessed by phase contrast microscopy. 
*Statistically significant difference between group and the no growth factor 
group (p < 0.05). †Statistically significant difference from the no growth 
factor and growth factor alone groups (p < 0.05). Bar = 200 µm. 
 
 37 
Figure 3.14  Glypisomes enhance VEGF induced endothelial tube formation. Endothelial 
cells grown on growth factor reduced matrigel and the cells were treated 
with glypisomes with varying composition and 10 ng/ml VEGF. After 16 
hours the formation of tubes was assessed by phase contrast microscopy. 
*Statistically significant difference between group and the no growth factor 
group (p < 0.05). †Statistically significant different from the no growth 
factor and growth factor alone groups (p < 0.05). Bar = 200 µm.   
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3.3.5 Glypisomes Increase FGF-2 Induced Signaling Through the AKT Pathway and 
Enhance Both FGF-2 Uptake and Endosomal Trafficking 
We examined whether glypican-1 proteoliposomes could increase the downstream 
signaling pathways induced by FGF-2. For the ERK1/2 pathway, we found that the cell 
signaling response with and without glypisomes was very similar (Figure 3.15A). 
However, for the AKT pathway there was a moderate increase in the AKT signaling after 
60 minutes (Figure 3.15B). Notably, neither pathway was appreciably activated by the 
glypisomes without the growth factor. To further explore the mechanism of glypisome 
enhancement of FGF-2 activity, we treated cells expressing GFP-labeled versions of the 
endosomal trafficking proteins Rab5, Rab7 or Rab11 with flurophore-labeled FGF-2 
(Figure 3.16). These proteins are markers of early (Rab5) and late (Rab7) endosomes as 
well as endosomal recycling (Rab11). We found increased numbers of Rab5 and Rab7 
positive endosomes that contained FGF-2 at all time points after 15 or 30 minutes, 
respectively, with treatment with glypisomes. At 120 minutes, there were increased 
numbers of Rab11 positive endosomes that contained FGF-2 in the glypisome treated 
group. We also measured the total cell fluorescence intensity for FGF-2 and found this 
was moderately increased for the glypisome group (Figure 3.17A). Finally, we measured 
the intensity of FGF-2 in the nucleus for the cells and found increased nuclear 
localization at the 15-minute time point for the glypisome group (Figure 3.17B). 
Together, these results support the notion that glypisomes have activity through a 
moderate enhancing effect on AKT signaling, by increasing FGF-2 uptake and through 
enhancing endosomal processing of FGF-2. 
 39 
 
Figure 3.15 Effect of glypisomes on the intracellular signaling response to FGF-2. 
Endothelial cells were serum starved and stimulated with 10 ng/ml FGF-2 
and/or glypisomes. The cells were lysed at various time points and western 
blotted for signaling mediators. *Statistically significant difference between 
group and control group (p < 0.05). 
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Figure 3.16  Glypisomes increase endosomal trafficking of FGF-2 in HEK-293 cells. (A) 
Quantification of the percentage of Rab5, Rab7 or Rab11 positive (GFP) 
endosomes that contained FGF-2 after treatment of HEK-293 cells with 
various conditions.  (B) Representative confocal images of cells treated with 
FGF-2 or FGF-2 with glypisomes at 120 min post treatment. *Statistically 
significant difference between the group and the FGF-2 only group at the 
same time point (p < 0.05). Bar = 20 µm. 
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Figure 3.17  Glypisomes increase total and early nuclear concentration of FGF-2 in cells. 
HEK-293 cells were treated with fluorescently labeled FGF-2 and fixed at 
various time points. The cells were stained with DAPI to define the nuclear 
area. The fluorescence was measured for (A) the total cell and (B) nuclear 
area from confocal images. *Statistically significant difference compared to 
the FGF-2 alone group (p < 0.05). **Statistically significant difference with 
FGF-2 with glypisomes group (p < 0.05). Bar = 20 µm. 
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3.4 DISCUSSION 
It has been challenging to develop angiogenic therapies that are effective in the 
context of human patients with disease. Here, we have shown that glypican-1 is reduced 
in the skin from patients with type 2 diabetes using immunohistochemical staining. This 
type of analysis is semi-quantitative but the large difference between the patient groups 
would support that there may be significant alterations in glypican-1 levels in diabetic 
patients. The implication of these findings is that loss of glypican-1 may contribute to 
reduced tissue sensitivity to growth factors and inhibit the response to angiogenic 
therapies. Consequently, in spite of high levels of growth factor delivered in a therapeutic 
context the tissue would likely not be able to mount an effective angiogenic response. 
Our approach to overcoming this potential mechanism of growth factor resistance was to 
create a therapy that can deliver the missing glypican-1 to the tissues without the need for 
gene therapies or the addition of exogenous cells. We delivered the glypican-1 embedded 
in a liposome membrane to simulate the endogenous glypican-1 presentation and to 
facilitate uptake of the protein. The formulation is stable when encapsulated in alginate 
and can be delivered locally to ischemic areas of the body. We show here that this 
method is very effective in increasing FGF-2 activity in vitro. 
Our in vitro studies revealed that glypisomes enhance growth factor activity but there 
were significant differences in the enhancement response between FGF-2 and VEGF. The 
proliferative response to FGF-2 was increased more by glypisomes than those stimulated 
with VEGF. In contrast, the cells simulated with VEGF and glypisomes had enhanced 
migration where FGF-2 simulated cells did not. Also, in the in vitro tube formation assay 
there were marked differences between VEGF and FGF stimulated network formation in 
the presence of glypisomes. The primary effect for cells treated with FGF-2 was an 
increase in branch points with a moderate increase in tube length. However, for cells 
treated with VEGF the effect was primarily an increase in the length of the tubes without 
little or negative effects on the branch points. Glypican-1 has been shown to increase the 
activity of both these growth factors [41, 44, 48] and the diversity of the response to 
glypisome may reflect the differences in the vascular networks that are induced FGF-2 
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and VEGF. For instance, FGF-2 is known to induce a strong proliferative response where 
as VEGF has been associated with a stronger effect on phenotypic differentiation [128]. 
This is reflected in the vascular networks that form when delivered exogenously with 
FGF-induced networks having fewer branch points and lower permeability than VEGF-
induced networks [128].  
Our studies demonstrated markedly increased uptake and concentration of FGF-2 in 
early (Rab5+) and late (Rab7+) endosomes. Prior studies have shown that glypican-1 
serves as a low affinity receptor for FGF-2 that stabilizes the FGF-2/FGF receptor 
complex.[44] In addition, heparan sulfate proteoglycans can serve as mediators of 
cellular uptake of FGF-2 [129]. Endogenous cell surface glypican-1 is known to be 
constitutively endocytosed in many cell types where its heparan sulfate chains are 
partially degraded and the protein is transported to the Golgi for glycosylation [130]. 
Upon activation, the FGF-2/FGFR1 complex is internalized through a clathrin-mediated 
mechanism and, subsequently, FGFR1 is found localized with first early endosomes and 
then late endosomes [131]. Our findings of increased FGF-2 signaling, uptake and 
endosomal processing are consistent with the hypothesis that exogenous glypican-1 acts 
similarly to endogenous glypican-1 in stabilizing the receptor-growth factor complex. 
However, we observed increased activity of the liposome-embedded glypican-1 in 
comparison to free glypican-1. The liposomal component may facilitate the uptake of a 
larger complex of FGF-2/FGFR-1 bound to a glypisome associated with additional FGF-
2 not bound to the receptor complex on the other parts of the liposome. This concept 
would explain how the glypisome could increase uptake significantly while having only 
moderate effects on the initial FGF-2 signaling.  
3.5 CONCULSIONS 
Here we have shown that we are able to purify recombinant glypican-1, and insert 
into a liposomal carrier to create the glypisomes. We have optimized the concentration of 
glypican-1 that leads to the greatest angiogenic response in several in vitro assays. The 
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glypisomes tend to yield the greatest angiogenic response when co-delivered with FGF-2, 
and while we see some response with when co-delivered with VEGF, it is significantly 
muted in all of our in vitro assays except for endothelial migration. We have also 
elucidated several possible mechanisms by which co-delivery of glypisomes with FGF-2 
may induce a pro-angiogenic response.  
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Chapter 4: In Vivo Validation of Glypisomes 
4.1 INTRODUCTION 
In the previous chapter we optimized the concentration concentrations of 
glypican-1 required to maximize angiogenic response in vitro and characterized a 
potential mechanism for this response. Now, using these glypisomes, we plan to examine 
their affectivity at overcoming disease associated growth factor resistance by testing them 
in a mouse hind limb ischemia model. For our in vivo models we plan to only look at co-
delivery with FGF-2, as we saw muted effects when co-delivered with VEGF165 in vitro. 
Initially we will look at the effect in healthy C57Bl/6 mice (WT) and then in the disease 
model, ob/ob mice. Previous work has shown that these ob/ob mice do in fact exhibit 
disease mediated growth factor resistance[4]. These in vivo experiments will give us a 
better idea of the efficacy of our glypisome and growth factor treatment. We plan to look 
at our treatments ability to induce angiogenesis initially in a wild type or healthy model 
of hind limb ischemia. Once we have shown that we are able to induce 
neovascularization in healthy animals we plan to move disease model, to see if we can 
overcome disease-induced growth factor resistance.  
4.2 MATERIALS AND METHODS 
4.2.1 Animal Studies 
Studies involving animals were performed with the approval of the University of 
Texas at Austin Institutional Animal Care and Use Committee (IACUC) and in 
accordance with NIH guidelines for animal care. Wild-type mice or ob/ob mice (B6.Cg-
Lepob/J; Jackson Labs) were used in the studies. The ob/ob mice were fed a high fat diet 
(Research Diets D12331) for 10 weeks prior to performing experiments. To perform the 
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hind limb ischemia studies, mice were anesthetized with 2% isofluorane gas and a 
longitudinal incision was made in the inguinal region of the right thigh. The femoral 
artery was separated from the femoral vein and nerve, and then double ligated with 6-0 
silk sutures at two locations and the artery severed at each ligation. Alginate beads 
containing the various treatments were then implanted in the pocket created by the 
surgery. A total of 3 µg FGF-2 and 19.5 ng of glypican-1 was implanted per mouse. The 
incision was then closed with vicryl sutures. Relative blood flow between the ischemic 
and contralateral control limb was measured at days 1, 3, 5, 7, and 14 using laser speckle 
imaging as described previously [132]. At day 14, the mice were sacrificed and the 
thigh/calf muscles were harvested and frozen in liquid N2 cooled isopentane. 
4.2.2 Immunostaining and Histological Analysis 
In the hind limb ischemia mouse model, the thigh and calf muscles were 
harvested from the mice, fixed in formalin and then processed for paraffin sectioning. 
The mouse tissue samples were cut with a microtome to obtain 6 μm thick sections were 
then stained using hematoxylin and eosin for overall morphology. The sections were 
deparaffinized and treated for 3 hours with antigen retrieval solution (Dako) at 80°C. The 
sections were cooled to room temperature and blocked with 20% fetal bovine serum for 
45 minutes and then immunostained with the Envision+ Dual Link Kit (Dako) using a 
1:100 dilution of primary antibody to PECAM-1 (Millipore) or a 1:500 dilution of 
primary antibody to glypican-1 (Thermo Scientific). Following staining, the samples 
were imaged using a bright field microscope (Meiji). For fluorescent immunostaining, the 
sections were treated as described as above but then treated with primary antibodies to 
glypican-1, PECAM-1 or a-SMA (Abcam). The staining was detected after treatment 
with fluorescently labeled secondary antibodies. The number of fibers with ischemic 
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changes was quantified in a minimum of three low magnification images per mouse. 
Histological sections from the contralateral limb were used as a control for artifacts of 
histological processing. Following immunostaining for PECAM-1, the number of small 
and large vessels was counted in images from each of the mice.  
4.2.3 Statistical Analysis 
All results are shown as mean ± standard error of the mean. Comparisons between 
only two groups were performed using a two-tailed Student’s t-test.  Multiple 
comparisons between groups were analyzed using a two-way ANOVA followed by 
Dunnett post-hoc testing. A two-tailed probability value of p < 0.05 was considered 
statistically significant. 
4.3 RESULTS 
4.3.1 Local Delivery of Glypisomes Enhances FGF-2 Induced Revascularization in 
the Ischemic Hind Limb of Wild Type Mice 
Both exogenous FGF-2 and VEGF have been shown to enhance revascularization 
in animal models of ischemia [133, 134]. Based on our in vitro studies, glypisomes 
appeared to be more effective in enhancing FGF-2 activity in comparison to VEGF. We 
induced hind limb ischemia in mice by ligating the femoral artery and implanted alginate 
beads that encapsulated FGF-2 or FGF-2 with the glypisomes (L20:P80; Figure 4.1). 
Perfusion in the ischemic limb and contralateral control limb was monitored using laser 
speckle imaging over 14 days. We found that glypisomes enhanced FGF-2 activity and 
lead to nearly twice the relative perfusion in the ischemic limb of glypisome treated mice 
after 14 days in comparison to those treated with FGF-2 alone (Figure 4.2A and Figure 
4.2B). Following the induction of ischemia, the muscle fibers can undergo ischemic 
changes that include the loss of fibers within the muscle. We quantified the number of 
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fibers with ischemic changes that appeared as holes on histological analysis (Figure 4.3A 
and Figure 4.3B). Care was taken to differentiate the ischemic changes from artifacts of 
histological processing by the sections to those from the non-ischemic control limb for 
each animal. This analysis demonstrated a marked reduction in the ischemic changes in 
the glypisome treated mice. Immunohistochemical staining for endothelial cells 
(PECAM-1) and subsequent analysis revealed increased capillary density in the thigh and 
calf muscles, consistent with the increased perfusion observed by laser speckle imaging 
(Figure 4.4A and Figure 4.4B). An analysis of larger vessels (diameter > 25 µm) revealed 
increased arteriogenesis in the thigh muscle of glypisome treated mice (Figure 4.4C).  
 
Figure 4.1 Glypisomes enhance therapeutic angiogenesis with FGF-2 in hind limb 
ischemia. (A) Optimal composition glypisomes were encapsulated in 
alginate beads. (B) Beads implanted at the site of injury at the time of 
surgery. 
BA
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Figure 4.2  (A) Laser speckle contrast imaging was used to assess blood perfusion in the 
feet of the mice over time. Mice were given either alginate beads with FGF-
2 or FGF-2 with glypisomes (G1PL). (B) Quantitative analysis of the 
perfusion of the feet after induction of hind limb ischemia. Relative blood 
flow was defined as the speckle contrast ratio between the ischemic limb 
and the control limb. *Statistically significant difference between the G1PL 
and G1PL + FGF-2 groups versus FGF-2 alone group at the same time point 
(p < 0.05).  
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Figure 4.3 (A) Histological analysis of the calf and thigh muscles of the ischemic limb 
after 14 days of treatment with FGF-2 or FGF-2 with glypisomes (G1PLs). 
(B) Ischemic changes in the muscle fibers were reduced in the calf muscle 
with FGF-2 and glypisome treatment in comparison to FGF-2 alone. 
Ischemic changes included the loss of muscle fibers/altered morphology 
with the tissue.   *Statistically significant difference with FGF-2 alone group 
(p < 0.05). Bar = 100 µm. 
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Figure 4.4  (A) Immunohistochemical staining for blood vessels (PECAM-1) in the 
thigh and calf muscles. (B) Quantification of small vessel density. (C) 
Quantification of large vessel density (diameter > 25 mm). *Statistically 
significant difference with FGF-2 alone group (p < 0.05). Bar = 100 µm. 
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4.3.2 Local Delivery of Glypisomes Enhances FGF-2 induced Revascularization in 
the Ischemic Hind Limb of Diabetic Mice 
We repeated a similar study in ob/ob mice that had been treated with a high fat 
diet for 10 weeks. These animals have severe diabetes and obesity, and our group has 
shown them to be resistant to FGF-2 stimulation [4]. In these animals, we found that 
glypisomes also improved perfusion recovery after femoral ligation (Figure 4.5). We did 
not see any significant differences in morphology of the muscle (Figure 4.6) however, 
our speckle data was confirmed by an increase in vascularization (Figure 4.7). Consistent 
with these findings, we found that there were less signs of ischemia in the toes of the 
animals treated with glypisomes (Figure 4.8). To examine if glypican-1 delivery led to 
changes in glypican-1 in the tissues of the mice treated with glypisomes, we 
immunostained sections from the ischemic limbs of the mice for PECAM-1 and glypican-
1. There was qualitatively higher diffuse glypican-1 staining within the muscles of the 
mice that had glypican-1 delivery (Figure 4.9). We further confirmed increased numbers 
of arterioles in the muscles of the mice by performing co-immunostaining for PECAM-1 
and α-SMA (Figure 4.10). 
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Figure 4.5 Glypisomes enhance therapeutic angiogenesis when delivered with FGF-2 
in an ob/ob hind limb ischemia model. (A) Quantitative analysis of laser 
speckle contrast imaging gives relative blood flow analysis of perfusion 
measured over time. Relative flow defined as perfusion in the ischemic limb 
over the perfusion in the contralateral limb. (B) Representative laser speckle 
contrast images of each treatment group at 1, 3, 5, 7, and 14 days post 
injury. Right paw is from ischemic limb and left is the contralateral control. 
*Statistically significant difference with FGF-2 alone group (p < 0.05).  
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Figure 4.6 Representative H&E stained muscle fiber cross-sections of the calf and 
thigh of the ischemic limb.  
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Figure 4.7  (A) Immunohistochemical staining for PECAM in calf and thigh muscle 
tissue of the ischemic limb. (B) Quantification of small vessel density in the 
calf and thigh muscle tissue, and large vessel density in the thigh muscle 
tissue. *Statistically significant difference from all other groups (p < 0.05). 
**Statistically significant difference from alginate group (p < 0.05). Bar = 
100 µm. 
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Figure 4.8  Glypisomes aid in preventing limb loss in an ob/ob hind limb ischemia 
model. Quantitative analysis of toe health at day 14 of the ob/ob hind limb 
ischemia study. Paws were scored from 0-4. A score of 0 indicates toes are 
normal, 1 indicates mouse had black toenails, 2 indicates a single black toe, 
3 indicates multiple black toes, and 4 indicates that all toes are black. 
Bracket used to indicate significant difference (p < 0.05). 
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Figure 4.9  Delivery of glypisomes increases glypican-1 present in the muscle tissue of 
the ob/ob mice. Immunostaining for glypican-1 and PECAM in the calf 
muscles from the limbs of ob/ob mice that underwent femoral ligation. Bar 
= 50 µm. 
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Figure 4.10  Glypisomes increase the number of α-SMA positive blood vessels following 
ischemic injury. (A) Immunostaining for α-SMA and PECAM in the thigh 
muscles from the limbs of ob/ob mice that underwent femoral ligation. (B) 
Quantification of a-SMA positive vessels in the thigh muscles from the 
ob/ob mice with femoral artery ligation. *p < 0.05 versus the alginate group. 
Bar = 50 µm. 
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4.4 DISCUSSION 
We delivered the glypican-1 embedded in a liposome membrane to simulate the 
endogenous glypican-1 presentation and to facilitate uptake of the protein. The 
formulation is stable when encapsulated in alginate and can be delivered locally to 
ischemic areas of the body. We show here that this method is very effective in increasing 
FGF-2 activity when locally delivered to the ischemic limb in wild type or diabetic mice. 
Our in vivo studies found that glypisomes enhanced growth factor activity in both 
wild type and ob/ob mouse models. In our studies, the perfusion of the hind limbs of the 
ob/ob mice recovered to a greater extent than wild type mice with treatment with FGF-2 
and glypisomes. Depending on the disease state the diabetic mice may undergo ischemic 
conditioning (i.e. their disease induces ischemia which can cause the growth of collateral 
vessels). In this case, the high fat diet may serve to induce ischemic conditioning in the 
ob/ob mice, facilitating their recovery from femoral ligation.  
In addition to its effects on angiogenesis, glypican-1 has been found to be 
important in the regulation of myogenic satellite cell proliferation and differentiation [40, 
135, 136]. Critical limb ischemia is often found in severe cases of peripheral vascular 
disease and leads to muscle atrophy in addition to many other symptoms [137]. Our study 
found a marked decrease in ischemia-induced muscle fiber damage in glypisome treated 
mice. Thus, the strategy of exogenously delivering glypican-1 may act through both 
angiogenic and muscle preserving mechanisms to improve the response to FGF therapy 
in-vivo. Consequently, glypisomes may present a therapeutic for treating both the 
deleterious effects of peripheral ischemia and provide additional myoprotective benefits 
by providing increased levels of gypican-1 in the muscle.  
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4.5 CONCLUSIONS 
In summary, our study supports that glypisomes can markedly improve the 
effectiveness of growth factor therapies in the context of ischemia in the diabetic disease 
state. This conceptual archetype of delivering lost co-receptors to replace molecular 
alterations due to disease may be relevant to many potential therapeutic applications in 
which an undesirable change in tissue biology makes current therapies untenable. From 
the poor or equivocal results of many clinical trials using growth factors it is clear that 
growth factor therapy alone is not sufficient to treat human disease in many cases.  
Therefore, therapeutic enhancers such as glypisomes are needed to truly address the 
complexities of growth factor responsiveness in the context of human disease.  
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Chapter 5: Glioblastoma Exosomes as a Therapy for Peripheral Limb 
Ischemia 
5.1 INTRODUCTION 
Exosomes are nanoparticles that are secreted by cells into their environment and 
range from approximately 30 to 100 nm in diameter [53]. These secreted extracellular 
vesicles are formed initially by formation of invaginations in the endosomal membrane to 
create a multivesicular body (MVB) [54]. This process is in contrast to that for 
microvesicles (200-1000 nm in diameter) that are formed by membrane shedding [55].  
Exosomes are released through multivesicular endosomal fusion with the plasma 
membrane and are found in many biofluids. These secreted vesicles have now been 
recognized as mediators of cell-cell communication, capable of delivering molecules 
between distant cells[56]. Exosomes, in particular are known to have high levels of 
tetraspanins, trafficking/export-related molecules and heat shock proteins [57-60]. In 
addition, exosomes contain proteins, microRNA (miRNA) and, in some cases, double 
stranded DNA [61, 62]. In addition, exosomes carry bioactive lipids including 
sphingomyelin, eicosanoids, cholesterol and ganglioside GM3 [63]. Extracellular vesicles 
including exosomes are efficiently taken up by cells in culture where they modify the 
target cells transcriptional and protein expression profiles.  
In particular, exosomes from many cell types have been known to mediate 
angiogenesis [64-69]. Exosomes derived from mesenchymal stem cells have also been 
shown to induce angiogenesis and modulate revascularization in ischemia and wound 
healing [68, 69]. Glioblastoma is one of the most angiogenic tumors, induce an intense 
growth of surrounding blood vessels [70]. The exosomes secreted by glioblastoma cells 
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prime endothelial cells to respond to hypoxic conditions with an angiogenic response 
[71]. Moreover, primary glioblastoma cells carry angiogenic miRNAs and proteins that 
facilitate angiogenic differentiation of endothelial cells [72]. Extracellular vesicles from 
glioblastoma cells have been shown to carry proteins that have both oncogenic and tumor 
suppressive activities including EGF receptors, PDGFR-A and PTEN [72-75]. Thus, 
while it is well supported that glioblastoma exosomes enhance angiogenesis it is less 
clear what role they play in tumor progression and metastasis. In addition, glioma-derived 
exosomes have immunomodulatory effects and drive macrophages towards the M2-
phenotype [76]. Macrophages polarized towards the M2-phenotype secrete VEGF and 
promote angiogenesis [77, 78]. 
 Exosomes are an emerging therapeutic strategy and have been explored as 
direct treatments for disease and drug carriers [79-82]. Exosomes from mesenchymal 
stem cells have generated significant interest and have been used to induce angiogenesis 
in wound healing and in ischemia [69, 83]. In addition, mesenchymal stem cell exosomes 
have improved the recovery following myocardial infarction and enhance cardiac 
regeneration [84, 85]. In this study, we aimed to examine using glioblastoma exosomes as 
therapeutics for enhancing revascularization in peripheral limb ischemia. Glioblastoma is 
one the most highly vascularized solid tumors and produces an intense angiogenic 
response. Moreover, the exosomes produced by these cells have been linked to growth 
promoting signals in endothelial cells [86]. Here, we explored whether this powerful 
aspect of tumor biology could be harnessed to enhance angiogenic therapies for patients 
with peripheral vascular disease.  
 63 
5.2 MATERIALS AND METHODS 
5.2.1 Cell Culture 
Human umbilical vein endothelial cells (HUVECs) were purchased from 
Promocell, Inc. and glioblastoma cells (A-172) were purchased from ATCC. The 
HUVECs were cultured in MCDB-131 medium with 7.5% FBS, EGM-2 supplements 
(Lonza), L-glutamine and antibiotics. The glioblastoma cell line (A-172) was cultured in 
DMEM with 10% FBS, L-glutamine, and antibiotics. Both cell lines were grown at 37°C 
and in a 5% CO2 atmosphere. 
5.2.2 Purification of Exosomes 
A glioblastoma cell line (A-172) was cultured to 60% confluence. Then cells were 
rinsed with PBS and the media was replaced with media containing exosome depleted 
FBS (20%) cultured for 48 hrs. The media was collected and exosomes were isolated 
from the media using the Exoquick-TC isolation kit (Systems Bioscience) and stored in 
PBS with magnesium in at -80°C. The number of exosomes was normalized to the 
exosome cell surface marker CD63 using a CD63 ELISA (Systems Bioscience). The 
number of exosomes was normalized to the exosome cell surface marker CD63 using a 
CD63 ELISA (Systems Bioscience). 
5.2.3 Exosome Characterization 
The size of the exosomes was measured using dynamic light scattering (Malvern 
Zetasizer Nano ZS). The instrument was calibrated using 54-nm diameter polystyrene 
particles and the exosomes were diluted in order to fit the detection region of the 
instrument. Final results were an average of 50 size measurements. For imaging the 
exosomes with cryo-electron microscopy, the samples were plunge-frozen in liquid 
ethane on carbon film grids as previously described (R2x2 Quantifoil; Micro Tools 
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GmbH, Jena, Germany).[138] The grids were then transferred to a cryo-specimen holder 
(Gatan 626) under liquid nitrogen and imaged using a transmission electron microscope 
(JEOL 2100 LaB6) operating at 200 keV. Grids were maintained at low temperatures 
during imaging session (-172°C to -180°C). The exosomes were imaged at 20,000x EM 
magnification with a 4000 x 4000 slow-scan CCD camera (UltraScan 895, GATAN, Inc.) 
using low-dose imaging procedure. ELISA’s were used to quantify presence of glypican-
1 (Ray Biotech) and syndecan-4 (Takara Clontech). 
5.2.4 Proteomic Analysis with Mass Spectroscopy 
Glioblastoma (A-172) cells were cultured to 70% confluence and then media was 
changed to exosome-depleted media. The media was collected 48 hours later and the 
exosomes were isolated using ExoQuick TC (Systems Bioscience). The exosomes were 
then processed with the XPEP Complete procedure. Nano LC/MS/MS was used to 
analyze the peptide libraries with a Waters NanoAcquity HPLC system and a 
ThermoFisher Q Exactive. The peptides were loaded on a trapping column and then 
eluted at 350nL/min using a 2 hr reverse phase gradient over a 75 µm analytical column. 
The columns were packed with Jupiter Proteo resin (Phenomenex). An injection volume 
of 30 µL was used. The mass spectrometer was used in data dependent mode, the orbitrap 
was set to 60,000 FWHM for MS and 17,500 FWHM for MS/MS. 
5.2.5 Exosome RNA Sequencing 
The glioblastoma cell line (A-172 cells) was grown to 70% confluence in 10 cm 
tissue culture plates. The media was changed to exosome-depleted media and cells were 
cultured for 48 hrs. The media was the collected and exosomes were isolated from the 
media using ExoQuick TC (Systems Bioscience). The total RNA was taken from the 
isolated exosomes using TRIzol. The quality of the isolated RNA was assessed using the 
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Agilent Bioanalyzer 2100 from the Functional Genomics Laboratory in the University of 
California in Berkeley. A RIN score of over 9 qualified the sample for cDNA production. 
To construct the library, one microgram of total RNA was used to isolate poly(A) 
purified mRNA. Average fragment sizes were 400 bp. Sequencing was done with an 
Ilumina HiSeq 2500 and each sample had 25-29 million 100-bp end reads. Read 
alignment was done by mapping to the mouse reference genome (UCSC/mm9) using 
Tophat [139], and HTSeq [140] was used to sum mapped reads for gene expression 
levels. DEseq [141] was used to normalize the read counts. 
5.2.3 Proliferation Assay 
Human Umbilical Vein Endothelial Cells (HUVECs) were cultured 70% 
confluence and then media was changed to low serum media (2% FBS, no growth factors 
added) and incubated for 24 hrs. The cells were then passaged into a 96 well plate at 2500 
cells/well and exosomes (4.4 or 30 * 108/ml) and/or FGF-2 (10 ng/ml) was added to the 
cells. BrdU was added to the cells 24 hrs post treatment. Then proliferation was assessed 
by BrdU incorporation at 12 hrs thereafter using a BrdU Assay (Cell Signaling). 
5.2.3 In Vitro Angiogenesis Assay 
The differentiation of endothelial cells was measured using an in vitro tube 
formation assay. Briefly, culture plates were coated with growth factor reduced matrigel 
at 37°C for 1 hour. In each well, 20,000 cells were seeded in the presence of different 
treatments with exosomes (4.4 or 30 * 108/ml) or FGF-2 (10 ng/ml). After 16 hours, the 
cells were imaged using phase contrast microscopy. Quantification of the number of 
branch points and tube length was performed using MetaMorph software (Molecular 
Devices). 
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5.2.5 Mouse Model of Hind Limb Ischemia 
Wild type C57BL/6 mice were used in the hind limb ischemia studies. Wild type 
mice were maintained on a normal mouse chow diet. The mice were anesthetized with 
isofluorane gas and the femoral artery was exposed through an incision in the inguinal 
region. The artery was separated from the femoral nerve and vein, and then ligated in two 
locations using a 6-0 silk suture. Alginate beads containing the exosomes (15 billion 
exosomes/mouse) and FGF-2 (1.5 µg/mouse) were implanted in a total volume of 200 µl. 
The incision was then closed using degradable sutures. Relative blood flow between the 
ischemic and contralateral control limb was measured at days 1, 3, 5, 7, and 14 using 
laser speckle imaging as described previously.[132] Briefly, the hind paws of the mouse 
were illuminated by a 785 nm, 50 mW laser diode (Thor Labs) and imaged using a 
Zoom-7000 lnse (Navitar) and a Bassler CCD camera. Relative perfusion for the hind 
limb ischemia study was quantified and normalized to the contralateral limb as a control. 
At day 14, the mice were sacrificed and the tissues of the hind limb were harvested and 
frozen in liquid N2 cooled isopentane. All animal procedures were approved by the 
Institutional Animal Care and Use Committee of UT Austin and were performed in 
accordance with the Guide for the Care and Use of Laboratory Animals published by the 
National Institutes of Health. 
5.2. Statistical Analysis 
All results are shown as mean ± standard error of the mean. Comparisons between 
only two groups were performed using a 2-tailed Student’s t-test.  Differences were 
considered significant at p < 0.05. Multiple comparisons between groups were analyzed 
by 2-way ANOVA followed by a Tukey post-hoc test. A 2-tailed probability value p < 
0.05 was considered statistically significant. 
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5.3 RESULTS 
5.3.1 Characterization of Size and Morphology of Glioblastoma Exosomes 
We isolated exosomes from the glioblastoma cell and analyzed them using cryo-
electron microscopy. We found a heterogeneous mix of vesicles that were predominantly 
in the range of 30-100 nm but also included a significant portion of larger microvesicles 
and exosomes aggregates (Figure 5.1). A DLS analysis of the size distribution included 
two peaks with maximums of 28 and 164 nm (Figure 5.2). Our group has recently shown 
that delivery of syndecan-4 or glypican-1 containing vesicles enhances angiogenic 
growth factor therapy.[4, 127] We performed an ELISA for syndecan-4 and glypican-1 
on the exosomes and found that there were high concentrations of both proteins in the 
isolated exosomes (Figure 5.3). 
 68 
Figure 5.1  Characterization of exosomes isolated from glioblastoma cell line. Cryo-
electron microscopy of exosomes. We observed heterogeneous mix of 
vesicles within the isolate, including exosomes and microvesicles. Bar = 100 
nm.  
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Figure 5.2  Dynamic light scattering analysis of isolated vesicles.  
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Figure 5.3 Concentration of syndecan-4 (SDC-4) and glypican-1 (GPC1) in exosomes 
isolated from glioblastoma cells quantified by ELISA and normalized to 
number of exosomes using CD63. 
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5.3.2 RNA expression and Proteomic Analysis of Exosomes 
We ran next generation RNA sequencing on the exosome samples to look at the 
RNA content of the isolated exosomes and identified the top 25 most abundant miRNA 
(Figure 5.4A and Figure 5.4B). We then looked at the angiogenic potential of these 
miRNA and categorized their association with cancer proliferation and metastasis (Table 
5.1). The most abundant was miR-221 which has been linked to new vascular 
formation[142], this particular miRNA was present at 3 fold higher levels than any other 
miRNA we detected (Figure 5.4B).   
 
Figure 5.4 (A) Types of RNA present in the isolated exosome samples. (B) The top 25 
most common miRNA detected in the isolated glioblastoma exosomes and 
their relative abundance. 
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Table 1, Most Abundant miRNA in Glioblastoma Exosomes 
Abundance miRNA Function 
62746.87 miR-221 Plays a role in new vessel formation[142, 143], upregulates 
proliferation[144] and migration[145] 
21170.88 miR-320a Inhibits cell proliferation and migration[146, 147] [147]  
10553.53 miR-21 Encourages angiogenesis[148, 149] may be anti-oncogenic[150] 
promotes metastasis[151] and proliferation[152] 
10512.92 miR-24 Downregulates cardiac tissue angiogenesis[153], upregulates tumor 
angiogenesis and apoptosis[154], upregulates 
proliferation/metastasis[155] 
6984.64 Let-7b Linked to reduced tumor angiogenesis[156], inhibits glioblastoma 
cell migration[157]  
6080.81 miR-1246 Linked to increased angiogenesis[158] promotes growth and 
metastasis[159] 
5493.73 Let-7a Inhibits glioma malignancy[160] 
5449.64 Mir-103 Upregulates VEGF, angiogenesis[161], metastasis[162] 
downregulates proliferation[163] 
5231.52 miR-107 Upregulates angiogenesis post stroke[164], downregulates tumor 
angiogenesis[165] 
4000.5 miR-122 Inhibits tumor proliferation[166] inhibits metastasis[167] 
3233.59 mir-423 Upregulates proliferation[168] 
3161.65 mir-25 Associated with glioma progression[169] 
2786.89 mir-23a Down regulates angiogenesis[170], increases glioma 
progression[171] 
2703.36 mir-16 Suppresses angiogenesis[172], leads to apoptosis[173],  inhibits 
metastasis[174] 
5491.41 let-7f Inhibits tumor proliferation[175], inhibits metastasis[176] 
2477.11 mir-320b Downregulates proliferation[177] 
2391.25 mir-27b Downregulates VEGF-C[178], upregulates tumor 
proliferation[179] and metastasis[180] 
2284.51 miR-378a Upregulates angiogenesis and tumor proliferation[181] 
2178.93 miR-27a Promotes proliferation and migration[182] 
1909.75 mir-486 Promotes angiogenesis and proliferation[183]  
1762.4 Let-7i Leads to cell death[184] 
1700.91 miR-93 Induces angiogenesis, proliferation, and migration[185] 
1500.19 mir-199a Downregulates angiogenesis[186] and proliferation[187]  
1500.19 mir-199b Promotes angiogenesis[188] promotes cell proliferation and 
migration[189] 
1367.92 mir-30a Promotes angiogenesis[190] and migration[191], can lead to 
apoptosis[192] 
 
Table 5.1 Table of the 25 most abundant miRNA’s in the isolated exosomes. Each 
miRNA’s role in angiogenesis (if any), and their role in cancer proliferation 
or metastasis (if any) are also described. 
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5.3.3 Glioblastoma Exosomes Enhance Proliferation and Tube Formation in 
Endothelial Cells 
We next examined whether exosomes could alter the behavior of endothelial cells 
in culture. We applied exosomes and exosomes with FGF-2 to cultured endothelial cells 
and measured their proliferation. We found that high levels of exosomes had synergistic 
activity with FGF-2 in increasing endothelial cell proliferation (Figure 5.5). We next 
tested the effect of exosomes in altering tube formation in endothelial cells. The 
exosomes increased the number of branch points and number of tubes formed at lower 
concentrations (Figure 5.6). In addition, the exosomes reduced the tube length of the 
network formed both with and without FGF-2 treatment. 
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Figure 5.5  Glioblastoma exosomes increase endothelial cell proliferation. Proliferation 
of endothelial cells measured by BrdU incorporation after 24 hours of 
treatment with 10 ng/ml FGF-2 and/or exosomes (108/ml). *Statistically 
significant different from groups treated with low concentration of 
exosomes with and without FGF-2 (p < 0.05). **Statistically significant 
difference from the control (p < 0.05).  
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Figure 5.6 Glioblastoma exosomes reduce tube length in tube formation assay (A) 
Quantification of tube length and tubes per field of view (B) Endothelial 
cells were grown on matrigel and treated with exosomes (108/ml) and/or 10 
ng/ml FGF-2. After 16 hours the formation of tubes was assessed by phase 
contrast microscopy. *Statistically significant difference from control group 
(p < 0.05). †Statistically significant difference from FGF-2 and FGF-2 with 
low exosome dose groups (p < 0.05). Bar = 200 µm. 
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5.3.4 Local Delivery of Glioblastoma Exosomes Enhances Therapeutic Angiogenesis 
in the Ischemic Hind Limb of Mice 
The delivery of FGF-2 enhances revascularization in animal models if 
ischemia.[4, 127] Our group has recently shown that delivering proteoliposomes that 
contain syndecan-4 or glypican-1 in combination with growth factors markedly improves 
revascularization in health and diabetic animals.[4, 127] We created ischemia in the hind 
limb of mice by ligating the femoral artery and implanted alginate beads with FGF-2 or 
FGF-2 and exosomes (Figure 5.7A and Figure 5.7B). We monitored perfusion in hind 
limbs for 14 days. Exosomes enhanced the recovery of perfusion in the hind limbs, with 
the exosomes and FGF-2 restoring approximately 75% of the perfusion relative to the 
control limb after 14 days  (Figure 5.8A and Figure 5.8D). We found that there was a 
reduction in the ischemic muscle fiber changes (Figure 5.9). In addition, we 
immunostained for the vessels within the muscles and found increased capillary density 
in the thigh and calf muscles, consistent with the increased perfusion observed by laser 
speckle imaging (Figure 5.10A and Figure 5.10B). An analysis of larger vessels revealed 
increased arteriogenesis in the thigh muscle of exosomes-treated mice (Figure 5.10C). 
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Figure 5.7  Glioblastoma exosomes enhance therapeutic angiogenesis with FGF-2 in 
hind limb ischemia. (A) Glioblastoma exosomes were encapsulated in 
alginate beads.  (B) Ischemia was induced in mice through femoral artery 
ligation and the alginate beads were implanted at the time of surgery.  
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Figure 5.8 Glioblastoma exosomes lead to increased recovered relative perfusion in a 
mouse hind limb ischemia model. (A) Perfusion of the feet after induction of 
hind limb ischemia. Relative blood flow was defined as the ratio between 
the ischemic limb and the control limb. *Statistically significant difference 
with the FGF-2 alone group at the same time point (p < 0.05). (B) Laser 
speckle contrast imaging analysis of blood perfusion in the feet of the mice 
over time. Mice were given either alginate beads with FGF-2 or FGF-2 with 
glioblastoma exosomes. 
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Figure 5.9  Exosomes reduce muscle damage and enhance vascularity of the ischemic 
hind limb in mice. (A) Histological sections from the hind limb of mice with 
femoral artery ligation. (B) Ischemic changes in histology were reduced in 
the calf muscle with FGF-2 and exosomes treatment in comparison to FGF-
2 alone. *Statistically significant difference with FGF-2 alone group (p < 
0.05). Bar = 100 µm. 
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Figure 5.10 Exosomes lead to an increased (A) Immunohistochemical staining for 
PECAM-1 (blood vessels) in the muscles of the limb. (B) Quantification of 
small vessel density within the muscles. (C) Quantification of large vessel 
density (diameter > 25 µm) within the muscles. *Statistically significant 
difference with FGF-2 alone group (p < 0.05). Bar = 100 µm. 
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5.4 DISCUSSION 
Exosomes are emerging therapeutics with applications ranging from cancer to 
cardiovascular disease. Several groups have shown that are benefits from exosomes from 
mesenchymal stem cells and, indeed, these effects may underlie the benefits of cell 
therapy in clinical trials. Tumors require an ever-increasing vascular supply to maintain 
their rapid growth within the native tissue. In particular, glioblastomas show intense 
angiogenesis that maintains their growth within the brain. Here, we aimed to test if the 
strong pro-angiogenic properties of tumor exosomes could be harnessed to treat ischemia 
in peripheral vascular disease. In the past, angiogenic therapies have not fared well in 
clinical trials. Thus, a robust angiogenic stimulus from multiple sources within tumor 
exosomes may provide benefit where a single growth factor or gene would not. Here, we 
show that exosomes from glioblastoma can effectively induce angiogenesis in the context 
of ischemia. In particular, exosomes provided an angiogenic signal that potentiated the 
therapeutic potential of FGF-2 both in in vitro and in vivo assays of angiogenesis.  
Our analysis of the content of glioblastoma revealed that the most abundant 
miRNA found in our isolated glioblastoma exosomes was miR-221, which has been 
shown to play an important role in the formation of new blood vessels [142]. This 
miRNA has been linked specifically to angiogenesis in glioblastoma [193] and increased 
glioblastoma cell proliferation [144]. Of the 25 most common miRNAs present in the 
isolated exosomes, nine have been shown to promote angiogenesis while only four have 
been shown to inhibit angiogenic pathways. Interestingly many of the miRNA also have 
been shown to promote cell proliferation and metastasis. 
Together these signals constitute a robust and multi-pathway angiogenic stimulus. 
In addition, our group has recently shown that proteoliposomes carrying proteoglycans, 
including both syndecan-4 and glypican-1, are highly effective in enhancing growth 
factor therapies [4, 127]. This is particularly important for inducing therapeutic 
angiogenesis in disease states such as diabetes, where there is a loss in these critical 
growth factor receptors [4]. Our results suggest that exosomes act in mechanisms in 
addition to direct stimulation of angiogenesis in endothelial cells. Our results from the 
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tube formation assay show an increase in branch points with exosomes treatment but a 
reduction in tube length. This may suggest that exosomes induce very dense vascular 
network formation. In our study, the exosomes provided intense growth signals to 
endothelial cells. In vivo, the exosomes enhanced FGF-2 induced revascularization. We 
found, however, that this result was primarily from capillary growth in calf muscles 
rather than arteriogenesis. This is consistent with our findings in the tube formation assay 
that showed small capillary-like branching.  
5.5 CONCLUSIONS 
We have shown that glioblastoma exosomes have potential as therapeutics for 
ischemia. Our studies support that the exosomes strongly induce angiogenesis in vivo and 
contain a host of pro-angiogenic signals that act through multiple mechanisms. This 
would likely be highly beneficial as treatments for severe ischemia given the presence 
therapeutic resistance in long-term disease that may prevent efficacy of single growth 
factors or genes. Thus, cancer derived exosomes as therapeutics may be applicable to 
many disease states and conditions that would benefit form enhanced capillary formation. 
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Chapter 6: Conclusions and Future Work 
6.1 CONCLUSIONS 
We have shown that glypican-1 is down regulated in the long-term disease state 
associated with peripheral limb ischemia. We have demonstrated that co-delivering 
growth factors with glypisomes also leads to greater angiogenic response in vitro by 
increasing endothelial proliferation, migration and tube formation. We have found 
evidence that this response may be due to increased uptake and increased AKT signaling.  
We then demonstrated the effectiveness of glypisomes co-delivered with FGF-2 
to increase the recovered relative perfusion, using a hind limb ischemia model, in both 
wild type and disease model mice. We also saw an increase of large vessel and small 
vessel density both the calf and thigh muscle tissue in these mice. In the disease model 
we saw a significant decrease in toe damage following the induced ischemia as a result of 
co-delivering FGF-2 and the glypisomes, suggesting that they are an effective therapy for 
peripheral limb ischemia. 
Finally we isolated exosomes from glioblastoma, and found that they contained 
glypican-1 and syndecan-4, which have been shown to enhance growth factor activity [4, 
194]. We also found that they contain many proangiogenic miRNA. When co-delivering 
these exosomes with FGF-2 we see a significant increase in endothelial proliferation. We 
saw that in a wild type hind limb ischemia model, co-delivering exosomes and FGF-2 
leads to an increase in recovered relative perfusion following the femoral ligation injury. 
This treatment also lead to an increase in vascular density and a reduction of muscle fiber 
damages. This suggests that glioblastoma exosomes may be an appealing treatment for 
therapeutic angiogenesis. 
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6.2 FUTURE WORK 
6.1 Intracellular Trafficking of Glypican-1 
To further understand why we see a greater angiogenic response to the 
glypisomes we will look at endosomal trafficking of the delivered glypican-1. To do this 
we will use the constructs for expressing GFP-Rab5, GFP-Rab7 and GFP-Rab11 (early, 
mid and late endosomal markers) described previously [195]. To study the effect of 
glypisomes on endosomal trafficking, HEK 293 cells will be transfected with the 
constructs using lipofectamine 2000 (Life Technologies, inc.) to express each of these 
GFP labeled Rab proteins. We will conjugate Alexa Fluor 594 to glypican-1 using a kit 
(ThermoFischer) to label these proteins in solution and then re-isolate them using the his-
tag on the labeled glypican-1. Then, these Alexa Fluor 594 labeled glypican-1 proteins 
will be incorporated into our glypisomes. Twenty-four hours after transfection, we will 
add the glypisomes and/or FGF-2 to the cells and then fix them at various time points. 
Using confocal microscopy we will image the cells and the percentage Rab-positive 
endosomes that are also glypican-1 positive will be quantified using 10 cells at each time. 
We also plan to repeat these experiments but rather than labeling FGF-2 with Alexa Fluor 
594 we plan to label the glypican-1 used for the glypisomes. . 
 
6.2 Wound Healing 
Determine therapeutic potential for wound healing in a disease model mouse 
excisional wound model. To assess glypisomes as a potential therapeutic for non-healing 
diabetic foot ulcers we should use an excisional wound model with ob/ob mice as the 
disease model. A To prevent wound healing contraction I propose the use of the silicon 
splint wound healing model. Here a wound is created in the back of the mouse using a 
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biopsy punch and then a silicon splint of the same size is adhered to the surrounding skin 
and sutured into place. Alginate disks, containing either glypisomes and/or growth 
factors, would then be inserted in the wound bed. Over the course of two weeks we 
would monitor the wound healing process. On day 14 the mouse will be sacrificed and 
the wound will be biopsied and cut in half. One half will be fixed in 10% formalin for 
paraffin-embedded sectioning and the other half will be either snap frozen for later 
processing. Sections will be stained for M1 and M2 Macrophages (CD86 and CD163 
respectively), vascularity (PECAM-1), and cytokeritin to assess wound healing. If we see 
a favorable response we will repeat this experiment, however wounds will be excised at 
days 2 and 6 to allow us to characterize the temporal behavior of the immune response. 
Half of the wound will be digested for FACS analysis of M1 and M2 macrophages at 
each time point.  
My hypothesis is that co-delivery of glypisomes and growth factors will 
significantly increase wound-healing time. I expect that these wounds will close faster 
and show greater vascularization and re-epithelialization on day 14. I expect the wounds 
treated with both glypisomes and growth factors to also have a higher ratio of M2/M1 
macrophages than wounds treated with growth factors alone and to transition from M1 to 
M2 macrophages at a faster rate. This shows a healthy, faster wound healing process.  
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